Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.